

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**  
Date of Report (Date of earliest event reported): August 7, 2018

---

**Arrowhead Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-38042  
(Commission  
File Number)

46-0408024  
(IRS Employer  
Identification No.)

225 South Lake Avenue, Suite 1050, Pasadena, CA 91101  
(Address of principal executive offices) (Zip Code)  
Registrant's telephone number, including area code (626) 304-3400

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 2.02 Results of Operations and Financial Condition**

On August 7, 2018, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2018 third quarter financial results for the period ended June 30, 2018. A copy of the press release is furnished herewith as Exhibit 99.1.

*In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.*

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release, dated August 7, 2018.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 7, 2018

ARROWHEAD PHARMACEUTICALS, INC.

By:           /s/ Kenneth Myszkowski          

Kenneth Myszkowski  
Chief Financial Officer



**PRESS RELEASE**  
**Aug. 7, 2018**

**Arrowhead Pharmaceuticals Reports Fiscal 2018 Third Quarter Results**

- Conference Call and Webcast Today at 4:30 p.m. EDT

**PASADENA, Calif., Aug. 7, 2018** — Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 third quarter ended June 30, 2018. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.

**Conference Call and Webcast Details**

Investors may access a live audio webcast on the Company's website at <http://ir.arrowheadpharma.com/events.cfm>. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8452059.

A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8452059.

**Selected Fiscal 2018 Third Quarter and Recent Events**

- Made presentations at the EASL International Liver Congress, including:
    - Preclinical data on ARO-AAT, the second generation candidate for the treatment of alpha-1 antitrypsin deficiency liver disease
    - Preclinical data on ARO-HBV, the third generation clinical candidate for the treatment of chronic hepatitis B virus infection
    - Clinical data on ARC-520, a prior generation compound for HBV
-

- Presented preclinical data at various medical meetings on the growing pipeline, including data on two cardiometabolic candidates ARO-APOC3 and ARO-ANG3 and the first candidate targeting the lung, ARO-ENaC
  - Completed enrollment and dosing of the single ascending dose portion of the ongoing Phase 1/2 study of ARO-HBV and began dosing HBV patients in the multiple ascending dose portion of the study
  - Completed enrollment of the Phase 1 study of ARO-AAT
  - Received a positive EMA opinion on orphan designation for ARO-AAT, this follows orphan drug designation that was previously granted by the US FDA
  - Presented initial clinical data on ARO-AAT at the Alpha-1 National Education Conference, representing this was the first clinical data presented on the proprietary Targeted RNAi Molecule (TRiM™) platform
  - Announced that Amgen had administered the first dose of AMG 890, formerly ARO-LPA, in a Phase 1 clinical study, which earned Arrowhead a \$10 million milestone payment
-

## Selected Fiscal 2018 Third Quarter Financial Results

### ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)

OPERATING SUMMARY	Three Months Ended June 30,		Nine Months Ended June 30,	
	2018	2017	2018	2017
REVENUE	\$ 727,375	\$ 9,342,498	\$ 4,887,321	\$ 22,693,923
OPERATING EXPENSES				
Research and development	12,052,653	11,136,741	36,974,625	37,363,207
General and administrative expenses	4,594,441	3,919,921	12,679,822	12,076,412
TOTAL OPERATING EXPENSES	16,647,094	15,056,662	49,654,447	49,439,619
OPERATING LOSS	(15,919,719)	(5,714,164)	(44,767,126)	(26,745,696)
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES	313,702	194,423	1,077,919	3,097,287
NET LOSS	\$ (15,606,017)	\$ (5,519,741)	\$ (43,689,207)	\$ (23,648,409)
NET LOSS PER SHARE (BASIC AND DILUTED):	\$ (0.18)	\$ (0.07)	\$ (0.53)	\$ (0.32)
WEIGHTED AVERAGE SHARES OUTSTANDING	87,634,435	74,772,103	82,149,381	73,603,852
FINANCIAL POSITION SUMMARY	June 30,	September 30,		
	2018	2017		
CASH AND CASH EQUIVALENTS	\$ 27,995,386	\$ 24,838,567		
SHORT-TERM INVESTMENTS	32,484,708	40,769,539		
LONG-TERM INVESTMENTS	17,672,658	-		
TOTAL CASH RESOURCES (CASH AND INVESTMENTS)	78,152,752	65,608,106		
OTHER ASSETS	34,750,275	38,414,174		
TOTAL ASSETS	112,903,027	104,022,280		
TOTAL LIABILITIES	11,143,668	23,155,118		
TOTAL STOCKHOLDERS' EQUITY	101,759,359	80,867,162		
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 112,903,027	\$ 104,022,280		
SHARES OUTSTANDING	87,854,651	74,785,426		

## About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit [www.arrowheadpharma.com](http://www.arrowheadpharma.com), or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit <http://ir.arrowheadpharma.com/email-alerts>.

### Safe Harbor Statement under the Private Securities Litigation Reform Act:

*This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.*

### Contacts:

Arrowhead Pharmaceuticals, Inc.  
Vince Anzalone, CFA  
626-304-3400  
[ir@arrowheadpharma.com](mailto:ir@arrowheadpharma.com)

### Investors and Media:

LifeSci Advisors, LLC  
Brian Ritchie  
212-915-2578  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)  
[www.lifesciadvisors.com](http://www.lifesciadvisors.com)

**Source:** Arrowhead Pharmaceuticals, Inc.

###